Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics
Main Article Content
Abstract
Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.
Article Details
How to Cite
Dr Sanjay Kalra, Dr Saptarshi Bhattacharya, & Dr Shehla Shaikh. (2022). Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics. Indian Journal Of Clinical Practice, 33(5), 8–10. Retrieved from https://ojs.ijcp.in/IJCP/article/view/305
Issue
Section
Guest Editorial